Miniatura

Fitxers

681374.pdf (1.42 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2019-02-01

Llicència de publicació

cc-by (c) Delgado-Ortega et. al., 2019
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/171990

The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1007/s10198-018-0986-y

Resum

bjective: To assess the economic burden of epithelial ovarian cancer (EOC) in incident patients and the burden by disease stage in Spain. Methods: We developed a Markov model from a social perspective simulating the natural history of EOC and its four stages, with a 10-year time horizon, 3-week cycles, 3% discount rate, and 2016 euros. Healthcare resource utilization and costs were estimated by disease stage. Direct healthcare costs (DHC) included early screening, genetic counselling, medical visits, diagnostic tests, surgery, chemotherapy, hospitalizations, emergency services, and palliative care. Direct non-healthcare costs (DNHC) included formal and informal care. Indirect costs (IC) included labour productivity losses due to temporary and permanent leaves, and premature death. Epidemiology data and resource use were taken from the literature and validated for Spain by the OvarCost group using a Delphi method. Results: The total burden of EOC over 10 years was 3102 mill euros: 15.1% in stage I, 3.9% in stage II, 41.0% in stage III, and 40.2% in stage IV. Annual average cost/patient was 24,111 and it was 8,641; 14,184; 33,858, and 42,547 in stages I-IV, respectively. Of total costs, 71.2% were due to DHC, 24.7% to DNHC, and 4.1% to IC. Conclusions: EOC imposes a significant economic burden on the national healthcare system and society in Spain. Investment in better early diagnosis techniques might increase survival and patients' quality of life. This would likely reduce costs derived from late stages, consequently leading to a substantial reduction of the economic burden associated with EOC.

Matèries

Càncer d'ovari, Diagnòstic

Matèries (anglès)

Ovarian cancer, Diagnosis

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

DELGADO-ORTEGA, Laura, GONZÁLEZ-DOMÍNGUEZ, Almudena, BORRÀS ANDRÉS, Josep maria, OLIVA-MORENO, Juan, GONZÁLEZ‑HABA, Eva, MENJÓN, Salomón, PÉREZ, Pedro, VICENTE, David, CORDERO, Luis, JIMÉNEZ, Margarita, SIMÓN, Susana, HIDALGO‑VEGA, Álvaro, MOYA‑ALARCÓN, Carlota. The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study. _European Journal of Health Economics_. 2019. Vol. 20, núm. 1, pàgs. 135-147. [consulta: 23 de gener de 2026]. ISSN: 1618-7598. [Disponible a: https://hdl.handle.net/2445/171990]

Exportar metadades

JSON - METS

Compartir registre